Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?

Core Viewpoint - Jazz Pharmaceuticals (JAZZ) shares have increased by 3% over the past four weeks, closing at $139.51, with a potential upside of 38.9$193.83 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $150 to a high of$230, with a standard deviation of $23.90, indicating variability among analysts [2] - The lowest estimate suggests a 7.5% increase from the current price, while the highest estimate indicates a 64.9% upside [2] Analyst Sentiment - Analysts show strong agreement on JAZZ's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has risen by 10.5% over the past month, with nine estimates increasing and two decreasing [10] Zacks Rank - JAZZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could indicate an upside for JAZZ [9]